Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cost of behavioral messaging interventions for cardiovascular medication adherence.

The American journal of managed care·2026

Same author

A pilot qualitative study of patient understanding and perceptions of genetic counselors and cascade testing in the context of transthyretin cardiac amyloidosis.

Journal of genetic counseling·2026

Same author

Association between SGLT2 inhibitors and outcomes after heart transplant in patients with type 2 diabetes: A systematic review and meta-analysis.

Heart failure reviews·2026

Same author

Fifty Years From the First Framingham Risk Profile: Are We Getting Closer to Identifying and PREVENTing Subclinical Disease Progression?

Journal of the American Heart Association·2026

Same author

Usability and Acceptability Evaluation of a Digital Health Physical Activity Intervention among Older Family Caregivers of Patients with Heart Failure.

Applied clinical informatics·2026

Same author

Association of Cannabis use and Survival in patients with heart failure: A claims-based cohort study of commercially insured adults.

American heart journal plus : cardiology research and practice·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

End-point selection for acute heart failure trials.

Larry A Allen¹

¹Colorado Cardiovascular Outcomes Research Consortium and the Section of Advanced Heart Failure, Division of Cardiology, Department of Medicine, University of Colorado Denver, Anschutz Medical Campus, 12631 East 17th Avenue, Aurora, CO 80045, USA. larry.allen@ucdenver.edu

Heart Failure Clinics

|September 20, 2011

Summary

Selecting appropriate clinical trial endpoints for acute heart failure (AHF) therapies is complex. This review examines AHF trial endpoints, focusing on improving survival, patient well-being, and resource efficiency for better treatment selection.

More Related Videos

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Related Experiment Videos

Last Updated: May 29, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

Area of Science:

Cardiology
Clinical Trials
Pharmacology

Background:

Acute heart failure (AHF) treatment requires careful evaluation of therapeutic efficacy.
Selecting appropriate response variables (endpoints) in AHF clinical trials is challenging due to trade-offs between patient outcomes and resource utilization.

Purpose of the Study:

To review factors complicating endpoint selection in AHF clinical trials.
To discuss various endpoints used in recent and ongoing AHF studies.
To propose future directions for AHF endpoint design and standardization.

Main Methods:

Literature review of completed and ongoing acute heart failure clinical trials.
Analysis of factors influencing endpoint selection, including clinical significance and resource impact.
Synthesis of current endpoint practices and identification of areas for improvement.

Main Results:

Endpoint selection in AHF trials involves balancing improvements in patient survival, symptom relief, and healthcare costs.
A wide range of endpoints are currently employed, lacking consistent standardization.
Complexity arises from the need to demonstrate superiority without negatively impacting other key goals.

Conclusions:

Standardizing endpoints in AHF trials is crucial for comparing therapeutic approaches effectively.
Future research should focus on developing and validating robust, multi-faceted endpoints.
Optimized endpoint selection will facilitate clearer evidence for superior AHF therapies.